PDCI & H3 Survey on Private Payer Product Listing Agreements Interest, Experience & Expectations
Private payers – the community of insurers, Pharmacy Benefit Managers (PBMs) and employers in Canada – are starting to build internal competencies aimed at negotiating product listing agreements (PLAs) with pharmaceutical companies. For the past several years, private payers have raised concerns about increasing drug costs – particularly for specialty products. As the importance of access to the private market increases for manufacturers, it is imperative that all parties better understand what is happening with respect to PLAs in this segment. Unfortunately, given their confidential nature, little is known about the prevalence, objectives or content of such PLAs. More importantly, it is difficult to get a sense of interest, experience and expectation in this approach.
In an attempt to demystify this matter, PDCI Market Access (www.pdci.ca) and H3 Consulting (www.hthree.ca) are seeking your participation in a confidential, anonymized private payer product listing agreement survey. Customized surveys will be sent to drug manufacturers, private insurers and PBMs and should take 10 minutes or less to complete. The survey will aim to answer the types of questions described below.
Why should your company participate?
- Any company that participates and provides us with a participant code will receive the detailed anonymized responses from all the respondents.
- Your response will help drug manufacturers, insurers and PBMs navigate this important change in the private payer marketplace. Please take a few minutes to participate even if your company has not been involved in any private market PLA.
Are there risks to participate?
- There are NONE. The survey sponsors are not seeking any proprietary information and participants need not identify themselves in order to submit a response.
Who will benefit from the survey results?
- The entire market access community – drug manufacturers, insurers and PBMs – will gain much-needed insight.
Will PDCI/H3 commercially profit from the sale of the survey summary report?
No. PDCI and H3 will publicly release the report findings as this project is meant to improve understanding of the private payer PLA environment.
PDCI has experience conducting such surveys and produced a similar report on companies’ experience with the pan-Canadian Pharmaceutical Alliance in 2015 (please see: https://www.pdci.ca/policy_articles/PDCI_pCPA_Benchmarking_Survey_Report_October_2014.pdf).
Surveys will be sent to a targeted list of respondents next week (June 29, 2015) for completion but if you want more information or you have any questions on this initiative, please contact Courtney Abunassar (Courtney.Abunassar@pdci.ca), PDCI’s Manager of Market Access and Policy Research or Chris Bonnett (email@example.com), Principal of H3 Consulting.